A consolidated subsidiary of Mitsubishi Tanabe Pharma, Tai Tien Pharmaceuticals Co., Ltd., started marketing Livalo (pitavastatin), a hypercholesterolemia treatment agent (an HMG-CoA reductase inhibitor), in Taiwan on June 1, 2012.
A regulatory approval was obtained in January 2011.